Notice of Intent to Award a Blanket Purchase Agreement to a Single Firm for Sterilely Compounded Pharmaceuticals via 503B Compounding Pharmacies for Gallup Indian Medical Center
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
The Navajo Area Indian Health Service, Gallup Service Unit in Gallup, NM, intends to award a single Blanket Purchase Agreement (BPA) with Fagron Compounding Services LLC (UEI: F7QNV46N18Q4) doing business as Fagron Sterile Services for sterilely compounded pharmaceuticals from an FDA-designated 503B facility on an as-needed basis. Items include Phenylephrine 100mcg.ml, Succinylcholine 20mg/10ml, LET 5ml syringe, Oxytoxin 30 units in 500ml (sterile to sterile and API), Epinephrine 8mg per 250ml bag (or other strength/volumes of the same medications in IV bags as available and required on an as-needed basis). Products must be sterilely compounded in an FDA approved facility with a beyond use date of at least 30 days from manufacture.
The anticipated period of performance is:
Base Period: 2/1/2026-1/31/2027
Option Period One: 2/1/2027-1/31/2028
Option Period Two: 2/1/2028-1/31/2029
Option Period Three: 2/1/2029-1/31/2030
Option Period Four: 2/1/2030-1/31/2031
The applicable North American Industry Classification System (NAICS) code assigned to this procurement is 325412- Pharmaceutical Preparation Manufacturing with a small business size standard of 1,300 employees.
No further awards will be made unless the need for Gallup Indian Medical Center changes. The prospective BPA identified in this notice is sufficient at this time. The identified vendor has the capability to provide sterilely compounded pharmaceuticals in a 503B facility and market research indicates the vendor is the only source. In accordance with Part 12.201-1(e)(3)(i)(B), BPAs may be established with a single firm from which numerous individual purchases at or below the simplified acquisition threshold will likely be made in a given period.
Any other sources that believe they are capable of fulfilling the government requirements as described are encouraged to submit their capability statement, price lists, and catalogs to the point of contact below via email only and no later than 1/28/2026 at 10:00AM (MST). In the event additional BPAs are deemed to be in the best interest of the government, capable vendors may be contacted and be requested to establish a BPA with the Government.
This notice of intent is not a request for quotations and a solicitation will not be issued.
Primary Point of Contact:
Rodney Brown, Contract Specialist
Email: Rodney.Brown@ihs.gov